Over 30% of patients in intensive care develop multiple organ failure, with a mortality rate of over 40% when at least three organs are affected. Covid-19 has increased the number of cases even more. The existing dialysis systems were only able to support one organ at a time, and treating patients with multiple organ failure required complicated care protocols, using cumbersome equipment.
With their ADVOS Multi solution, Advitos (55 employees - 4M€ turnover) offers extra-corporeal assistance procedures capable of providing simultaneous support for kidney, lung and liver failure, while regulating blood ph balance. Not only does it improve patient treatment, but it also facilitates the work of the healthcare professionals and reduces the cost of treatment.
A totally unique dialysis device
“Advitos has developed a unique technology which has demonstrated its efficiency and has been certified” says Delphine Cardi, Principal at Crédit Mutuel Innovation. “They are supported by extremely involved business leaders who are internationally recognised experts in this area” adds Sébastien Neiss, Managing Director of Crédit Mutuel Equity in Germany, “This technology has also been supported for a long time by loyal investors”. Advantages which did not go unnoticed by Crédit Mutuel Innovation and the German team of Crédit Mutuel Equity, who participated equally as leading investors in the raising of 20M€ equity carried out by the Munich-based company, together with EIC Fund and a strategic investor specialising in dialysis.
Reproduce the German model internationally
Launched on the market in 2017, Advos Multi is now present in over 20 hospitals in Germany. This increase in capital will allow new functions to be added to the product, new clinical studies to be carried out in order to validate more accurate indications, and will also increase the domains of application and develop sales - first in Europe, then in the United States.
“With this round of financing, we will be able to implement major R&D development projects and accelerate the commercialisation of our device in order to allow as many patients as possible to benefit from it”, adds Bernhard Kreymann, founder and CEO of Advitos. “We are counting on our new partners to bring us their expertise and to open new doors for us.”